Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have earned a consensus rating of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $20.57.

A number of research firms have recently commented on CLBT. TD Cowen raised their price objective on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Craig Hallum raised their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. upped their price objective on Cellebrite DI from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Monday. Finally, Needham & Company LLC raised their target price on Cellebrite DI from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th.

Institutional Investors Weigh In On Cellebrite DI

A number of large investors have recently bought and sold shares of CLBT. Quarry LP bought a new position in Cellebrite DI in the 3rd quarter valued at $27,000. Point72 Asia Singapore Pte. Ltd. raised its holdings in shares of Cellebrite DI by 59.6% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock valued at $33,000 after buying an additional 1,017 shares during the last quarter. Advisors Asset Management Inc. lifted its position in Cellebrite DI by 130.5% during the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock worth $52,000 after buying an additional 1,742 shares in the last quarter. Pathway Financial Advisers LLC grew its holdings in Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock worth $74,000 after acquiring an additional 4,118 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado acquired a new stake in Cellebrite DI in the 2nd quarter valued at about $71,000. 45.88% of the stock is currently owned by institutional investors.

Cellebrite DI Stock Up 4.3 %

Cellebrite DI stock opened at $21.29 on Friday. The business has a 50 day moving average price of $19.14 and a two-hundred day moving average price of $16.02. Cellebrite DI has a 12 month low of $7.91 and a 12 month high of $21.72. The stock has a market cap of $4.38 billion, a price-to-earnings ratio of -13.74, a price-to-earnings-growth ratio of 2.71 and a beta of 1.51.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The business had revenue of $106.90 million during the quarter, compared to analyst estimates of $102.06 million. During the same period in the prior year, the company posted $0.09 earnings per share. Cellebrite DI’s revenue was up 27.0% on a year-over-year basis. On average, analysts expect that Cellebrite DI will post 0.32 earnings per share for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.